CNSP CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas.

$2.65
As of 03/03/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
USA
USA
12/31/1997
25,300,868
3,150,773
$67,047,300
0.00%
SEC Edgar Online
10-Q
10-K
18978H102
US18978H1023
BKPTPZ1

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
94.64
0.00
-67.81%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy